Gastrointestinal Cancer

Futibatinib is now approved to treat patients with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. The agent comes with warnings for ocular toxicities, and hyperphosphatemia and soft tissue mineralization.

Kristin Barber, APRN, AOCNP, FNP-BC, unpacks the FDA approval of durvalumab in combination with cisplatin and gemcitabine for patients with biliary tract cancers.

Selpercatinib was approved by the FDA for RET fusion–positive non–small cell lung cancer and locally advanced or metastatic RET fusion–positive solid tumors.

Patients with hepatocellular carcinoma achieved a median overall survival of 15.9 months with tislelizumab and 14.1 months with sorafenib.

After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.

A multicentre, retrospective study showed that treatment-related adverse effects associated with atezolizumab plus bevacizumab were prognostic of improvements in survival outcomes in patients with hepatocellular carcinoma.

Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.

Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.

In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.

Expert perspectives on how to best manage adverse events associated with trastuzumab emtansine while treating patients with breast or gastric cancers.

Shared insight on the clinical utility of trastuzumab emtansine in the second- and third-line settings of breast and gastric cancers.

The FDA has approved durvalumab for patients with advanced or metastatic biliary tract cancers. The immunotherapy comes with warnings for immune-related adverse events and infusion reactions.

Best management strategies for vancomycin infusion reactions may include premedication, infusion-rate adjustment, and, in some cases, alternative antibiotic therapy.

Shifting focus to a patient profile of HER2+ metastatic breast cancer treated with trastuzumab emtansine, oncology nurse experts review risk of peripheral neuropathy and its management.

Closing out their conversation on the first patient profile, oncology nurse experts consider sequencing therapy following trastuzumab deruxtecan in both breast and GI cancers.

Younger women who underwent endoscopies had a reduced risk of colorectal cancer incidence, according to findings of a prospective cohort study.

A combination of niraparib plus ipilimumab were associated with a 6-month PFS rate of 59.6%, whereas a combination of nivolumab plus the PARP inhibitor yielded a rate of 20.6%.

When combined with neoadjuvant chemotherapy, galunisertib induced complete response rates surpassing rates achieved with standard-of-care therapy in locally advanced rectal cancer.

Comprehensive insight to the selection and education of patients for whom ADC therapy is an option in breast or gastric cancers, with regard for pulmonary risk status.

Focused conversation on the occurrence of interstitial lung disease in patients on antibody drug conjugate therapy for breast or gastric cancers.

Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.

Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.

Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.

An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.

In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.

An expert of gastrointestinal oncology with the Henry Ford Cancer Institute discusses the developing presence of targeted treatments in the pancreatic cancer treatment paradigm.